[go: up one dir, main page]

DK1373529T3 - Tau-opati model - Google Patents

Tau-opati model

Info

Publication number
DK1373529T3
DK1373529T3 DK02702181T DK02702181T DK1373529T3 DK 1373529 T3 DK1373529 T3 DK 1373529T3 DK 02702181 T DK02702181 T DK 02702181T DK 02702181 T DK02702181 T DK 02702181T DK 1373529 T3 DK1373529 T3 DK 1373529T3
Authority
DK
Denmark
Prior art keywords
tau
alzheimer
disease
opati
model
Prior art date
Application number
DK02702181T
Other languages
English (en)
Inventor
Leuven Freddy Van
Joris Winderickx
Original Assignee
Remynd Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9909505&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1373529(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Remynd Nv filed Critical Remynd Nv
Application granted granted Critical
Publication of DK1373529T3 publication Critical patent/DK1373529T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Signal Processing For Digital Recording And Reproducing (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
DK02702181T 2001-02-26 2002-02-25 Tau-opati model DK1373529T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0104685.3A GB0104685D0 (en) 2001-02-26 2001-02-26 Tau-opathy model
PCT/BE2002/000022 WO2002068663A1 (en) 2001-02-26 2002-02-25 Tau-opathy model

Publications (1)

Publication Number Publication Date
DK1373529T3 true DK1373529T3 (da) 2008-08-18

Family

ID=9909505

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02702181T DK1373529T3 (da) 2001-02-26 2002-02-25 Tau-opati model

Country Status (8)

Country Link
US (1) US20050009019A1 (da)
EP (1) EP1373529B1 (da)
AT (1) ATE393229T1 (da)
DE (1) DE60226220T2 (da)
DK (1) DK1373529T3 (da)
ES (1) ES2306755T3 (da)
GB (1) GB0104685D0 (da)
WO (1) WO2002068663A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799535B1 (en) 1997-12-09 2010-09-21 Arch Development Corporation Methods for identifying factors that control the folding of amyloid proteins of diverse origin
ATE532874T1 (de) * 2001-02-15 2011-11-15 Univ Chicago Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen
AU2004231746A1 (en) * 2003-04-16 2004-11-04 Whitehead Institute For Biomedical Research Yeast ectopically expressing abnormally processed proteins and uses therefor
EP2709728B1 (en) * 2011-05-20 2019-01-23 Oligomerix, Inc. Tau protease methods of use
GB201319656D0 (en) 2013-11-07 2013-12-25 Univ Leuven Kath A yeast model for synergistic toxicity
SG11201608084TA (en) * 2014-04-17 2016-10-28 Boehringer Ingelheim Rcv Gmbh Recombinant host cell engineered to overexpress helper proteins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003369A1 (en) * 1991-08-01 1993-02-18 Voorheis Paul H Diagnostic method for alzheimer's disease
KR940021073A (ko) * 1993-03-02 1994-10-17 미야베 요시가즈 알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i
CA2157774A1 (en) * 1993-04-07 1994-10-13 Christopher John Marshall Methods for screening of substances for therapeutic activity and yeast for use therein
GB9316727D0 (en) * 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
US5691137A (en) * 1994-08-30 1997-11-25 Brandeis University Methods of screening candidate agents for biological activity using yeast cells
US5952217A (en) * 1997-09-23 1999-09-14 Bristol-Myers Squibb Company Recombinant yeast cell and assay using same
US7799535B1 (en) * 1997-12-09 2010-09-21 Arch Development Corporation Methods for identifying factors that control the folding of amyloid proteins of diverse origin
NZ515956A (en) * 1999-07-02 2004-04-30 Janssen Pharmaceutica Nv Transgenic animals as models for neurodegenerative disease
GB0100119D0 (en) * 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease

Also Published As

Publication number Publication date
DE60226220D1 (de) 2008-06-05
WO2002068663A1 (en) 2002-09-06
ES2306755T3 (es) 2008-11-16
US20050009019A1 (en) 2005-01-13
EP1373529A1 (en) 2004-01-02
ATE393229T1 (de) 2008-05-15
DE60226220T2 (de) 2009-08-20
EP1373529B1 (en) 2008-04-23
GB0104685D0 (en) 2001-04-11

Similar Documents

Publication Publication Date Title
DK1641483T3 (da) Fusionsproteiner
BR0215383A (pt) proteases que produzem resposta imunogênica alterada e métodos de fabricação e uso das mesmas
ECSP088262A (es) Proteínas de fusión de albúmina
HUP0202882A2 (en) Novel b7-4 molecules and uses therefor
DE60330923D1 (de) Menschliche Koagulationsfaktor VII Polypeptide
EP1289551A4 (en) HUMAN POLYPEPTIDES THAT LEAD TO THE DISAPPEARANCE OF CELLS, IN PARTICULAR LYMPHOID TUMOR CELLS
EP1751282A4 (en) PRODUCTION OF HOST CELLS CONTAINING MULTIPLE INTEGRATED VECTORS THROUGH SERIAL TRANSDUCTION
WO2009001260A3 (en) Cosmetic use of apolipoprotein d type proteins
ATE487737T1 (de) 32 humane sekretierte proteine
DK1373529T3 (da) Tau-opati model
WO2000068247A3 (en) Serine proteases
WO2001062891A3 (en) 207 human secreted proteins
ATE464320T1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
CY1111004T1 (el) Χρησιμες συνθεσεις για τη ρυθμιση της δρασης του γονιδιου της παρκινης
ATE539086T1 (de) Interleukin-11-fusionsproteine
ATE503834T1 (de) Bibliotheken rekombinanter chimärischer proteine
WO2003082206A3 (en) Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
DE60142356D1 (de) 18480 humane proteinkinasemoleküle und ihre verwendungen
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells
WO2005035564A3 (en) Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
DE60237236D1 (de) Ein mitglied der menschlichen proteinkinasefamilie, und verwendungen dafür
ATE343632T1 (de) Mutiertes nurr1 gen
WO2002099066A3 (en) 20 human secreted proteins
DE60231816D1 (de) Menschliche alpha2-delta4-calciumkanal-untereinheit codierende cdna
AU2002350406A1 (en) Identification of ses-3 (spr-5) in c. elegans and the uses of the same